Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Elsevier 2019

Antzeko izenburuak

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
nork: Williamson, K, et al.
Argitaratua: (2018)

Vedolizumab for the treatment of chronic pouchitis
nork: Travis, S, et al.
Argitaratua: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
nork: Renske W. M. Pauwels, et al.
Argitaratua: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
nork: Suzanne I. Anjie, et al.
Argitaratua: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
nork: Matthew Luzentales-Simpson, et al.
Argitaratua: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
nork: Pulusu, S, et al.
Argitaratua: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
nork: Kothari M, et al.
Argitaratua: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
nork: Igor L. Khalif, et al.
Argitaratua: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
nork: A. O. Golovenko, et al.
Argitaratua: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
nork: Judy A. Trieu, et al.
Argitaratua: (2017-12-01)

Vedolizumab-Induced Liver Injury
nork: Miguel Mascarenhas Saraiva, et al.
Argitaratua: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
nork: Ledder, O, et al.
Argitaratua: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
nork: Ledder, O, et al.
Argitaratua: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
nork: Beatriz Gros, et al.
Argitaratua: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
nork: de Vries, E, et al.
Argitaratua: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
nork: Prasanta Debnath, et al.
Argitaratua: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
nork: Martine Walmsley, et al.
Argitaratua: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
nork: Bhayat, F, et al.
Argitaratua: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
nork: Ledder, O, et al.
Argitaratua: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
nork: Feagan, B, et al.
Argitaratua: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
nork: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Argitaratua: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
nork: Asaf Levartovsky, et al.
Argitaratua: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
nork: Travis, S, et al.
Argitaratua: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
nork: Feagan, BG, et al.
Argitaratua: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
nork: Abdulaziz Saad Alshahrani, et al.
Argitaratua: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
nork: S. K. Zyryanov, et al.
Argitaratua: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
nork: Kira L. Newman, et al.
Argitaratua: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
nork: Merve Sivridaş, et al.
Argitaratua: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
nork: Fares Ayoub, et al.
Argitaratua: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
nork: Bryant, R, et al.
Argitaratua: (2015)

A product review of vedolizumab in inflammatory bowel disease
nork: Robert Battat, et al.
Argitaratua: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
nork: Benjamin Crooks, et al.
Argitaratua: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
nork: Feagan, B, et al.
Argitaratua: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
nork: Shahed Kamal, et al.
Argitaratua: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
nork: Bhayat, F, et al.
Argitaratua: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
nork: Bye, W, et al.
Argitaratua: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
nork: Jenifer González Chávez, et al.
Argitaratua: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
nork: Eddie Y. Liu, et al.
Argitaratua: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
nork: Kaituo Huang, et al.
Argitaratua: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
nork: Thomas Schiestel
Argitaratua: (2023-03-01)